JP2022512384A5 - - Google Patents

Info

Publication number
JP2022512384A5
JP2022512384A5 JP2021533435A JP2021533435A JP2022512384A5 JP 2022512384 A5 JP2022512384 A5 JP 2022512384A5 JP 2021533435 A JP2021533435 A JP 2021533435A JP 2021533435 A JP2021533435 A JP 2021533435A JP 2022512384 A5 JP2022512384 A5 JP 2022512384A5
Authority
JP
Japan
Prior art keywords
purified
asph
tumor
vaccine
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021533435A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512384A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/066174 external-priority patent/WO2020123912A1/en
Publication of JP2022512384A publication Critical patent/JP2022512384A/ja
Publication of JP2022512384A5 publication Critical patent/JP2022512384A5/ja
Pending legal-status Critical Current

Links

JP2021533435A 2018-12-13 2019-12-13 Asph発現腫瘍の成長および進行の阻害 Pending JP2022512384A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862779422P 2018-12-13 2018-12-13
US62/779,422 2018-12-13
PCT/US2019/066174 WO2020123912A1 (en) 2018-12-13 2019-12-13 Inhibition of asph expressing tumor growth and progression

Publications (2)

Publication Number Publication Date
JP2022512384A JP2022512384A (ja) 2022-02-03
JP2022512384A5 true JP2022512384A5 (cg-RX-API-DMAC7.html) 2022-12-20

Family

ID=71077044

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021533435A Pending JP2022512384A (ja) 2018-12-13 2019-12-13 Asph発現腫瘍の成長および進行の阻害

Country Status (7)

Country Link
US (1) US20220054614A1 (cg-RX-API-DMAC7.html)
EP (1) EP3893925A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022512384A (cg-RX-API-DMAC7.html)
KR (1) KR20210129634A (cg-RX-API-DMAC7.html)
CN (1) CN113747914A (cg-RX-API-DMAC7.html)
CA (1) CA3123006A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020123912A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
WO2020223639A1 (en) * 2019-05-01 2020-11-05 Sensei Biotherapeutics, Inc. Combination therapies for cancer
EP4061405A1 (en) 2019-11-18 2022-09-28 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ597724A (en) * 2009-07-24 2013-10-25 Rhode Island Hospital Dendritic cell vaccines for asparaginyl-beta-hydroxylase expressing tumors
US20140271689A1 (en) * 2013-03-15 2014-09-18 Panacea Pharmaceuticals Therapeutic Cancer Vaccine Targeted to HAAH (Aspartyl-[Asparaginyl]-beta-Hydroxylase)
EA201690912A1 (ru) * 2013-11-05 2016-10-31 Когнейт Биосервисис, Инк. Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака
WO2015164826A2 (en) * 2014-04-24 2015-10-29 Rhode Island Hospital ASPARTATE-β-HYDROXYLASE INDUCES EPITOPE-SPECIFIC T CELL RESPONSES IN TUMORS
GB201501017D0 (en) * 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
US10995140B2 (en) * 2015-06-05 2021-05-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. GM-CSF/CD40L vaccine and checkpoint inhibitor combination therapy
SG11201808196UA (en) * 2016-03-31 2018-10-30 Neon Therapeutics Inc Neoantigens and methods of their use
WO2019217913A1 (en) * 2018-05-10 2019-11-14 Sensei Biotherapeutics, Inc. Aspartate beta-hydroxylase chimeric antigen receptors and uses thereof

Similar Documents

Publication Publication Date Title
Mathew et al. Combining chemotherapy with PD-1 blockade in NSCLC
KR102470294B1 (ko) 암을 치료하기 위한 항-pd1 항체 및 방사선의 조합
JP7162535B2 (ja) 抗gitr抗体およびその使用
CN106573977B (zh) 针对ceacam1的人源化抗体
US11684656B2 (en) Combination therapy for malignant diseases
AU2016229810A1 (en) Compositions and methods for enhancing the efficacy of cancer therapy
JP2022514499A5 (cg-RX-API-DMAC7.html)
JP2023036999A (ja) 免疫応答を調節するためのオキサビシクロヘプタン
JP7384896B2 (ja) 主要組織適合遺伝子複合(mhc)クラスii-発現癌細胞ワクチン、及び統合免疫応答を生じさせるための使用方法
CN112351795A (zh) 采用抗癌药剂和以包含非典型hla-i及新抗原复合物为靶点的抗体的联合抗癌疗法
JP2020528449A5 (cg-RX-API-DMAC7.html)
JP2021528367A (ja) 免疫応答を誘導するための組成物
US20210179714A1 (en) Inhibition of CTLA-4 and/or PD-1 For Regulation of T Cells
WO2020216963A1 (en) Personalized immunotherapy for treatment of cancer
KR20240103062A (ko) 이중 특이적 항CD3 x MUC16 항체 및 항CTLA-4 항체로 암을 치료하는 방법
TW202304512A (zh) 雙特異性t細胞銜接體之給藥
TWI814752B (zh) 免疫治療劑、核苷類抗代謝物和鉑類聯合在製備治療腫瘤的藥物中的用途
RU2021104042A (ru) Иммунотерапия, нацеленная на антигены kras или her2
Subudhi et al. Improving the Therapeutic Benefits of Ipilimumab
HK40005871B (en) Anti-gitr antibodies and uses thereof
HK40005871A (en) Anti-gitr antibodies and uses thereof
Turcotte et al. PolyI: C and CpG synergize with anti-ErbB2 mAb for treatment of breast tumors resistant to immune checkpoint inhibitors.